ICC panel rules in flu drug dispute
North Carolina-based Biocryst Pharmaceuticals has reported a favourable ICC award terminating its agreement with an Australian-owned company for licensing of the world’s first intravenous flu treatment.
To read more
Subscribe to Global Arbitration Review
Subscribe and start reading now
Global Arbitration Review (GAR) is the online home for international arbitration specialists, telling them everything they need to know about all the developments that matter.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10